ProCE Banner Activity


Therapeutic Strategies for HER2-Positive Breast Cancer: Exploring Clinical Trial Data and a Treatment Sequence Algorithm


Watch this on-demand webcast featuring expert presentations and discussion of the latest data on the treatment of HER2-positive breast cancer.

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 06, 2023

Expiration: April 05, 2024



Aditya Bardia

Aditya Bardia, MD, MPH

Director, Breast Cancer Research
Associate Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts

Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Provided by

This activity is provided by Clinical Care Options, LLC.

ProCE Banner


This activity is supported by educational grants from Puma Biotechnology, Inc. and Seagen Inc.

Puma Biotechnology, Inc.

Seagen Inc.

Target Audience

This program is intended for medical oncologists and other healthcare professionals who care for patients with breast cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to select and integrate new and emerging therapies into individualized treatment plans for HER2-positive breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan therapeutic strategies for HER2-positive early-stage breast cancer, considering available evidence, pathologic response to neoadjuvant therapy, expert recommendations, and an understanding of patient issues, challenges, and preferences

  • Integrate recent advances and available clinical data to optimally select first- and second-line HER2 targeted therapies for HER2-positive advanced breast cancer 

  • Plan therapeutic strategies for heavily pretreated HER2-positive breast cancer, considering detection of brain metastases, available evidence, and expert recommendations

  • Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for HER2-positive breast cancer

  • Identify patients with HER2-positive breast cancer eligible for enrollment on ongoing clinical studies investigating novel therapies 


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Aditya Bardia, MD, MPH: consultant/advisor: Daiichi Sankyo/AstraZeneca, Foundation Medicine, Genentech, Immunomedics/Gilead, Lilly, Menarini, Merck, Mersana, Novartis, Pfizer, Phillips, Radius Health, Sanofi; researcher (paid to institution): Daiichi Sankyo/AstraZeneca, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Radius Health, Sanofi.

Erika P. Hamilton, MD: researcher (paid to institution): AbbVie, Acerta, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan-Florentine, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR, Ellipses, Elucida Oncology, EMD Serono, FujiFilm, G1 Therapeutics, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind, Leap, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Novartis, Nucana, Olema, OncoMed, Onconova, Oncothyreon, ORIC, Orinove, Orum, Pfizer, PharmaMar, Pieris, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix, Shattuck Labs, StemCentRx, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque, Treadwell, Verastem, Zenith, Zymeworks; consultant/advisor: Arcus, AstraZeneca, Daiichi Sankyo, Ellipses, Greenwich LifeSciences, iTeos, Janssen, Lilly, Loxo, Mersana, Novartis, Olema, Orum, Pfizer, Relay Therapeutics, Roche/Genentech, SeaGen, Stemline, Tubulis, Verascity Science.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.00 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 06, 2023, through April 05, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Continuing Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.